A systematic review has reported a surprising finding: some patients treated with rituximab for pemphigus experienced exacerbation of their condition rather than improvement. This paradoxical reaction presents a significant challenge for clinicians, who must balance the benefits of rituximab therapy with the potential for these adverse events. In a comprehensive review involving 63 patients, researchers meticulously analyzed the variables associated with these paradoxical outcomes, aiming to delineate risk factors and provide guidance in clinical decision-making.

Immune checkpoint modulation and the unique actions of biologic therapies complicate the presented clinical picture. Paradoxical responses may stem from a renewed immune reaction as rituximab decreases B-cell populations, potentially activating residual B-cells or T-cells that can lead to exacerbations of autoimmunity. Understanding the immunological backdrop of these reactions may provide insights into the pathophysiology of pemphigus itself, challenging conventional understanding and paving the way for novel therapeutic approaches.

The findings from the systematic review highlighted a range of clinical manifestations associated with rituximab-induced paradoxical reactions. In some instances, patients reported increased blister formation, while others experienced new lesions at sites previously unaffected by pemphigus. The variability in responses underscores the need for clinicians to remain vigilant when initiating rituximab therapy, tailoring each treatment plan to the individual patient’s history and response patterns.

Furthermore, this review raised questions regarding the timing of the paradoxical reactions post-rituximab administration, with some patients exhibiting symptoms soon after treatment initiation, while others experienced delayed onset. This temporal aspect of reactions is critical for understanding patient management and the long-term implications of monoclonal antibody therapy in autoimmune diseases.

Moreover, it is crucial to consider the genetic and environmental factors that might influence individual responses to rituximab. Future investigations should aim to identify biomarkers that could predict those at risk for adverse effects, allowing healthcare practitioners to make more informed decisions when selecting patients for rituximab therapy. Collaborative efforts between dermatologists, immunologists, and pharmacologists may enhance understanding and lead to refined treatment protocols.

As more data emerges regarding the paradoxical reactions to rituximab, there is hope for advancing treatment strategies for pemphigus. Clinicians are reminded of the importance of patient education, encouraging open communication about potential side effects and the necessity for close monitoring during treatment. With a better understanding of rituximab’s effects on the immune system, the goal remains to optimize therapeutic outcomes while minimizing adverse events.

The systematic review serves as a pivotal reference point for ongoing research in the field of autoimmune dermatology. By elucidating the paradoxical nature of certain reactions to rituximab, researchers are invited to delve deeper into the intricate interplay between therapy and immune dysregulation, fostering an environment where patient care continuously evolves based on scientific discovery. The findings may represent just the tip of the iceberg, stimulating further inquiry into the immunological mechanisms involved in autoimmune disorders.

Despite the complexities highlighted by the systematic review, it is essential to recognize the transformative nature of rituximab in the management of pemphigus. The drug continues to be an integral component of treatment regimens, offering hope to countless patients who struggle with the debilitating effects of this disease. As the field progresses, the challenge remains to harness the benefits of this powerful therapy while safeguarding against potentially life-altering complications.

In conclusion, the paradoxical reactions to rituximab in pemphigus patients underscore the need for a nuanced understanding of autoimmune therapies. Researchers and clinicians alike are charged with the responsibility of further exploring the underlying mechanisms and refining treatment strategies. As we advance our knowledge, it becomes increasingly vital to prioritize patient safety and outcome optimization, ensuring that therapies like rituximab continue to provide relief without unintended consequences.

The recent systematic review highlights an urgent need for vigilance and further research in pemphigus treatment. The findings echo throughout the dermatological community, igniting discussions on treatment modalities and the potential for personalized medicine in treating autoimmune conditions. As science continues to evolve, so too must our approach, ensuring that patient care remains at the forefront of therapeutic innovation.

As we look to the future, embracing multifaceted approaches that meld clinical practice with cutting-edge research may well yield the solutions needed to address these complex challenges in the management of pemphigus and beyond.

Subject of Research: Paradoxical reactions to rituximab in pemphigus patients

Article Title: Paradoxical reaction to rituximab in patients with pemphigus: a systematic review of 63 patients.

Article References:

Vahabi, S.M., Pourgholi, E., Ansari, M.S. et al. Paradoxical reaction to rituximab in patients with pemphigus: a systematic review of 63 patients.
Arch Dermatol Res 318, 49 (2026). https://doi.org/10.1007/s00403-025-04515-1

Image Credits: AI Generated

DOI: 10.1007/s00403-025-04515-1

Keywords: pemphigus, rituximab, paradoxical reactions, autoimmune disorders, treatment challenges, immune response, systematic review.

For decades, the scientific consensus held that the glucocorticoid receptor functions either as a monomer or as a canonical homodimer. However, recent cutting-edge research led by the University of Barcelona team introduces a paradigm shift by demonstrating that, inside the nucleus, GR predominantly forms tetrameric assemblies—structures composed of four receptor subunits. This fundamental insight into the receptor’s oligomerization redefines our understanding of its biological activity and opens an exciting avenue for drug development focused on modulating these precise protein interactions with unprecedented specificity.

The glucocorticoid receptor is integral to regulating the expression of around 20% of the human genome. It governs critical pathways including glycemic control, metabolism, and immune system modulation. Dysfunction in these pathways often manifests as autoimmune disorders, asthma, psoriasis, and even rare conditions such as Chrousos syndrome. The newfound evidence illustrating GR’s tetrameric state provides a molecular basis for developing new pharmaceuticals that do not just target the receptor’s ligand-binding site but also fine-tune its multimerization profile—potentially minimizing hazardous side effects like immunosuppression and osteoporosis commonly seen with current glucocorticoid therapies.

This comprehensive study, a product of a multidisciplinary collaboration encompassing institutions such as the US National Institutes of Health and several prominent Spanish and Argentinian research centers, leveraged an array of advanced methodologies. Among these were X-ray crystallography performed at the ALBA synchrotron facility, molecular dynamics simulations, high-resolution fluorescence microscopy, and mass spectrometry. The synergy of these techniques enabled the team to decipher not only the structural details of the GR complexes but also their dynamic conformational landscapes within the cellular milieu.

One of the most striking revelations pertains to the non-canonical nature of the GR homodimer, which contrasts sharply with the traditional models described for other nuclear receptors. The team found that the active dimeric building block forms through interactions involving specific helices in the ligand-binding domain. This non-classical dimer arrangement is foundational, serving as a modular element—a sort of molecular LEGO—assembled into higher-order oligomers, predominantly tetramers, that are essential for effective DNA binding and transcriptional regulation.

The flexibility of the GR oligomeric conformations was another captivating finding. Unlike rigid molecular machines, the GR exhibits pronounced plasticity in its dimer interfaces, fluidly transitioning between more open or closed states. This conformational malleability is hypothesized to be critical for the receptor’s ability to orchestrate complex transcriptional programs and respond to diverse cellular signals. The analogy of a molecular contortionist aptly describes the GR’s capacity to adopt numerous structural configurations, a feature that has historically hampered its comprehensive structural characterization.

Importantly, the study also casts light on the molecular pathology associated with mutations in the GR gene. It has long been known that certain mutations in the receptor’s ligand-binding pocket impair hormone binding and lead to functional deficits. This investigation extends that knowledge by cataloging mutations on the surface residues of the ligand-binding domain, which disrupt the receptor’s oligomerization process. Such alterations often promote aberrant formation of larger oligomeric states, such as hexamers and octamers, which display markedly diminished transcriptional activity. These findings elucidate the molecular underpinnings of glucocorticoid resistance seen in Chrousos syndrome and other immune and metabolic disorders.

By delineating the multimerization pathway of the glucocorticoid receptor and correlating specific structural perturbations with altered receptor function, the research provides a robust template for the design of next-generation glucocorticoid drugs. The prospect of generating precision therapeutics that selectively modulate GR oligomerization states holds promise not only for increasing treatment efficacy but also for drastically reducing the severe side effects associated with currently available glucocorticoid medications.

Moreover, understanding how GR’s structural assembly influences its interaction with cofactors and the broader transcriptional machinery invites further exploration into the receptor’s role in diverse pathological states beyond autoimmune diseases, including Cushing’s syndrome and Addison’s disease. The foundational knowledge gained through this work has the potential to catalyze a wave of biomedical research focused on harnessing the receptor’s inherent structural plasticity for therapeutic benefit.

The meticulous combination of structural and functional analyses presented in this study underscores the power of integrating experimental and computational approaches in tackling challenging biological questions. By applying techniques such as molecular dynamics simulations alongside experimental crystallography and fluorescence microscopy, the investigators have overcome formidable obstacles posed by GR’s intrinsic flexibility, providing an unprecedentedly detailed view of its active conformations within the nucleus.

Looking ahead, this paradigm-shifting research paves the way for future studies aimed at resolving the full three-dimensional architectures of the GR in complex with DNA and nuclear cofactors under physiological conditions. Such insights will be essential to fully comprehend the receptor’s transcriptional regulatory mechanisms and to exploit its multimerization dynamics for drug discovery.

In summary, the elucidation of the glucocorticoid receptor’s multimerization process fundamentally alters our conception of its functional biology. It highlights the receptor not as a static molecule but as a dynamic and adaptable master regulator, whose oligomeric versatility is key to its diverse physiological roles and whose modulation represents a promising strategy for innovative therapeutic intervention.

Subject of Research: Not applicable

Article Title: The multimerization pathway of the glucocorticoid receptor

News Publication Date: 21-Oct-2025

Web References:
https://academic.oup.com/nar/article/53/19/gkaf1003/8294360
http://dx.doi.org/10.1093/nar/gkaf1003

References:
Estébanez-Perpiñá E., Alegre-Martí A., Jiménez-Paniño A., Fuentes-Prior P., et al. “The multimerization pathway of the glucocorticoid receptor.” Nucleic Acids Research, 2025.

Image Credits: UNIVERSITY OF BARCELONA

Keywords: Molecular biology

Adoptive immunotherapy, especially CAR T cell therapy, has emerged as a powerful weapon against hematologic malignancies and other diseases by engineering a patient’s T cells to express CARs that recognize tumor antigens. Traditionally, this involves harvesting T cells from patients, genetically modifying them outside the body, expanding these cells, and reinfusing them—a process that requires extensive infrastructure, time, and significant costs. The reliance on ex vivo manipulation also exposes cells to potential contamination, and manufacturing variability can impact therapeutic efficacy. Addressing these limitations has been a persistent scientific challenge, one that has inspired new strategies centered on simplifying and streamlining T cell engineering.

Theresa Hunter and her team have pioneered a transformative method whereby lipid nanoparticles, engineered with a novel ionizable lipid designated L829, are conjugated with antibodies targeting CD5—a protein prominently expressed on T cells. These CD5-targeted LNPs are designed to evade the liver’s reticuloendothelial system, a common sink for systemically administered nanoparticles, thereby enhancing the specificity and efficacy of T cell delivery. By encapsulating mRNA encoding CAR constructs, the tLNPs facilitate the direct translation of these sequences within T cells in vivo, bypassing the integration risks associated with DNA-based vectors.

The advantages of utilizing mRNA are profound. Unlike DNA, mRNA remains transient in the cytoplasm and avoids genomic integration, mitigating concerns regarding insertional mutagenesis and other long-term genetic alterations. This transient expression can also be advantageous where temporary modulation of immune response is desired. Yet, the chief hurdle has been achieving selective and efficient in vivo delivery to T cells, which conventional LNPs have struggled with due to predominant hepatic accumulation and off-target effects.

By leveraging the specificity afforded by CD5-targeting and the biophysical properties of the ionizable lipid L829, the researchers achieved markedly improved biodistribution of their nanoparticles. In preclinical tests spanning murine, rat, and nonhuman primate models, these CD5-L829-tLNPs demonstrated reduced liver uptake and enhanced localization within T cell populations. Such precision in targeting heralds a new frontier in immunotherapy, allowing for more controlled, predictable therapeutic outcomes while limiting systemic toxicity.

Beyond biodistribution, the functional efficacy of these in vivo engineered CAR T cells was rigorously evaluated. Blood samples derived from patients with autoimmune disorders revealed that the tLNP approach could equip diseased T cells with CAR constructs at efficiencies paralleling those achieved with healthy donor cells. Impressively, these remodeled T cells selectively eliminated corresponding B cells responsible for pathogenic autoantibody production, suggesting potent therapeutic potential against autoimmunity.

To further corroborate the therapeutic promise, humanized mouse models, engrafted with primary human immune cells, were administered a single intravenous dose of the targeted nanoparticles. Within hours, recipient mice showcased robust B cell depletion that persisted for up to fourteen days, indicating not only rapid induction but also durable immune modulation via this novel approach. This in vivo paradigm minimizes the procedural complexities traditionally associated with adoptive cell transfer therapies.

Moreover, when applied in a leukemia xenograft model, repeated dosing of the tLNPs led to near-complete clearance of tumor burden. This outcome underscores the platform’s versatility and strength in mounting potent antitumor responses. The direct and scalable nature of in vivo CAR T cell generation may democratize access to these therapies, making effective immunotherapy feasible outside specialized centers and possibly reducing treatment costs.

The implications of this research extend beyond oncology, offering a blueprint for treating a spectrum of immune-mediated diseases. By enabling rapid, on-demand reprogramming of immune cells through safe, non-integrative mRNA delivery systems, this technology could hasten clinical responses and provide personalized treatment options for patients with refractory autoimmune conditions and beyond.

Despite these remarkable advancements, important considerations linger regarding the fine-tuning and clinical translation of this technology. The transient nature of mRNA expression could necessitate repeated dosing protocols, raising questions about immune memory formation and long-term efficacy. Furthermore, off-target immune activation and nanoparticle immunogenicity must be carefully monitored and mitigated through further optimization.

This approach exemplifies a paradigm shift in cellular immunotherapy, transitioning from cumbersome ex vivo manipulations to a seamless, minimally invasive in vivo reprogramming. As the field embraces this innovation, broader applications across infectious diseases, transplant medicine, and tolerance induction in autoimmune pathologies appear increasingly attainable.

In sum, the pioneering work of Hunter and colleagues heralds a transformative era where immunological engineering is not confined to manufacturing suites but can instead be delivered systemically with precision, safety, and efficacy. Targeted lipid nanoparticle-mediated delivery of functional mRNA directly to T cells paves the way for next-generation therapies that are more accessible, adaptable, and potent—a prospect poised to reshape the future of medicine.

Subject of Research: In vivo generation of CAR T cells using targeted lipid nanoparticles for cancer and autoimmune disease treatment

Article Title: In vivo CAR T cell generation to treat cancer and autoimmune disease

News Publication Date: 19-Jun-2025

Web References: http://dx.doi.org/10.1126/science.ads8473

Keywords: CAR T cells, in vivo engineering, lipid nanoparticles, mRNA delivery, immunotherapy, cancer treatment, autoimmune disease, targeted delivery, ionizable lipids, adoptive cell therapy, CD5 targeting, gene therapy